晚期乳头状肾细胞癌亚型分型的病理一致性率及结局
研究评估晚期乳头状肾细胞癌(PRCC)1型与2型分型在靶向治疗患者中的临床意义,以及局部病理复核与中心复核的一致性、敏感性和阳性预测值(PPV)。147例患者按局部复核亚型分层随机接受舒尼替尼或卡博替尼等治疗,中心复核由三位专家病理医生回顾性独立完成。结果显示局部与中心复核亚型分类频繁不一致,局部复核敏感性低,卡博替尼较舒尼替尼在1型和2型亚组中均改善无进展生存期(PFS)和客观缓解率(ORR),但亚型分型未识别出从卡博替尼获益更大的亚组。
要点
- 局部与中心复核PRCC亚型分类频繁不一致,局部复核敏感性低(1型48%,2型67%,NOS/混合型43%)。
- 卡博替尼较舒尼替尼改善1型和2型PRCC的PFS(1型7.4 vs 9.0个月;2型2.9 vs 5.6个月)及ORR。
- PRCC亚型分型未识别出从卡博替尼获益更大的亚组,与WHO 2022指南一致。
核心结论
- PRCC亚型分型未识别出从卡博替尼临床获益更大的患者亚组,局部与中心复核间存在显著不一致。
- 研究结果证实转移性PRCC病理亚型分型的临床价值有限,与近期世界卫生组织(WHO)2022指南一致。
研究设计与样本
- 晚期难治性PRCC患者按局部复核亚型(1型、2型或非特指[NOS]/混合型)分层随机接受舒尼替尼或卡博替尼、克唑替尼或沃利替尼治疗。
- 中心复核由三位泌尿生殖系统病理专家回顾性独立完成。
- 共复核147例患者,评估局部复核的敏感性和阳性预测值(PPV),并按中心复核亚型分层总结各治疗组的客观缓解率(ORR)和无进展生存期(PFS)。
主要发现
- 局部复核与中心复核的亚型患病率分别为:1型17.7% vs 29.3%;2型53.1% vs 45.6%;NOS/混合型29.3% vs 25.2%。
- 局部病理复核敏感性低:1型48%(95% CI 33, 65);2型67%(95% CI 55, 78);NOS/混合型43%(95% CI 27, 61)。
- 局部复核PPV分别为:1型80%,2型57.7%,NOS/混合型37%。
- 与舒尼替尼相比,卡博替尼在1型和2型PRCC亚组中均改善PFS(1型7.4 vs 9.0个月;2型2.9 vs 5.6个月)并提高ORR。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical significance of subtyping (type 1 vs 2) of papillary renal cell carcinoma (PRCC) in patients treated with targeted therapy, as well as the concordance, sensitivity and positive predictive value (PPV) of local review pathology review. METHODS: Patients with advanced refractory PRCC were randomised to receive sunitinib or cabozantinib, crizotinib or savolitinib, stratified by PRCC subtype (type 1, type 2, or not otherwise specified [NOS]/mixed) by local review. Central review was retrospectively conducted by three expert genitourinary pathologists who independently reviewed cases. The sensitivity and PPV of local review were estimated and outcomes [objective response rate (ORR), progression-free survival (PFS)] were summarised for treatment groups stratified by subtypes by central review. RESULTS: Amongst the 147 patients reviewed, the prevalence of individual subtypes varied by local or central review (type 1: 17.7% vs 29.3%; type 2: 53.1% vs 45.6%; NOS/mixed: 29.3% vs 25.2%), respectively. Individual cases were frequently reclassified and local pathology review demonstrated low sensitivity (type 1: 48%, 95% confidence interval [CI] 33, 65; type 2: 67%, 95% CI 55, 78; NOS/mixed: 43%, 95% CI 27, 61). The PPVs of local review were 80%, 57.7% and 37% for type 1, 2 and NOS/mixed, respectively. Compared to sunitinib, cabozantinib demonstrated improved PFS for both type 1 and type 2 PRCC subgroups (7.4 vs 9.0 and 2.9 vs 5.6 months, respectfully) as well as higher ORR. CONCLUSIONS: The PRCC subtype assignment did not identify a subset of patients with greater clinical benefit from cabozantinib, with significant discordance between local and central review. Our findings confirm the limited clinical value of pathological subtyping of metastatic PRCC, in line with the recent World Health Organisation 2022 guidelines. PATIENT SUMMARY: In this study, categorising papillary renal cell carcinoma into type 1 or 2 subtypes showed limited concordance between central and local pathological review and did not enrich for patients more likely to benefit from cabozantinib in the S1500 PAPMET trial.
引用
- Tripathi A, Tangen CM, Plets M, et al. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU Int. 2024. PMID: 39014969. doi:10.1111/bju.16403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。